Verastem Inc (VSTM)
0.664
-0.02 (-3.09%)
USD |
NASDAQ |
Jan 27, 16:00
0.6568
-0.01 (-1.08%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 132.86M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -53.24% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 33.90 |
| Price to Book Value | 2.113 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.04% |
News
Headline
Wire
Time (ET)
MT Newswires
01/25 08:01
MT Newswires
01/25 04:49
MT Newswires
01/25 04:34
SA Breaking News
01/24 18:20
Yahoo
01/24 17:46
Yahoo
01/18 16:05
Yahoo
01/11 06:24
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/28/2023* | -- | Results | Q4 2022 | -- | -0.10 | -- | |
| 11/03/2022 | -- | Results | Q3 2022 | -0.09 | -0.12 | 26.53% | |
| 08/08/2022 | -- | Results | Q2 2022 | -0.12 | -0.11 | -9.09% | |
| 05/09/2022 | -- | Results | Q1 2022 | -0.09 | -0.09 | -5.88% | |
| 03/28/2022 | -- | Results | Q4 2021 | -0.10 | -0.12 | 16.67% | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.13 | -0.07 | -85.71% | |
| 08/02/2021 | -- | Results | Q2 2021 | -- | -- | -- | |
| 05/11/2021 | -- | Results | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. |
| URL | https://www.verastem.com |
| Investor Relations URL | https://investor.verastem.com/events/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 28, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 75.74M |
| Net Income (TTM) | -73.48M |
| Total Assets (Quarterly) | 111.10M |
| Total Liabilities (Quarterly) | 48.22M |
| Shareholders Equity (Quarterly) | 62.87M |
| Cash from Operations (TTM) | -56.99M |
| Cash from Investing (TTM) | 53.23M |
| Cash from Financing (TTM) | 58.59M |
Ratings
Profile
Edit
| Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers. |
| URL | https://www.verastem.com |
| Investor Relations URL | https://investor.verastem.com/events/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Mar. 28, 2023 (est.) |
| Last Earnings Release | Nov. 03, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| VSTM Tweets |